Maged A Ghali, M.D.
Emeritus Professor
Department:
Medicine – Jacksonville
Business Phone:
(904) 244-8846
Business Email:
maged.ghali@jax.ufl.edu
About Maged A Ghali
Maged Ghali, M.D., is a University of Florida emeritus professor of medicine and a board-certified gastroenterologist and transplant hepatologist. Dr. Ghali received his medical degree from McGill University in Montreal, Canada. He completed his internal medicine residency and gastroenterology fellowship at McGill University Health Center-Royal Victoria Hospital. He also completed fellowship training in transplant hepatology at Mayo Clinic in Rochester, Minnesota.
Additional Positions:
Emeritus Professor
2024 – Current
·
University of Florida
Professor
2018 – 2024
·
University of Florida
Chief
2018 – 2024
·
Division Of Gastroenterology
Program Director
2018 – 2024
·
Gastroenterology Fellowship
Board Certifications
-
GastroenterologyAmerican Board of Internal Medicine
-
Transplant HepatologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Gastroenterology
- General Internal Medicine
- Transplant Hepatology
Subspecialties
- Gastroenterology
- Transplant Hepatology
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-5914-3231
Publications
Academic Articles
2023
Acute haemorrhagic ischaemic colitis secondary to cocaine use.
BMJ case reports.
16(9)
[DOI] 10.1136/bcr-2023-255704.
[PMID] 37666567.
2021
Esophageal Perforation after Using a Single-Use Disposable Duodenoscope.
Case reports in gastroenterology.
15(3):972-977
[DOI] 10.1159/000519685.
[PMID] 35110984.
2020
Multiple myeloma with hepatic amyloid light-chain amyloidosis manifesting as progressive liver failure.
BMJ case reports.
13(6)
[DOI] 10.1136/bcr-2020-234637.
[PMID] 32601138.
Grants
Jan 2024
– Dec 2024
Re-linkage to Care in the United States
Role: Other
Funding: CENTER FOR DISEASE ANALYSIS FOUNDATION
via GILEAD SCIENCES
Dec 2022
ACTIVE
An Open-Label Study to Evaluate the Safety and Tolerability of Volixibat in Patients with Primary Biliary Cholangitis Currently Being Treated with Obeticholic Acid
Role: Principal Investigator
Funding: SYNEOS HEALTH
via MIRUM PHARMACEUTICALS
Feb 2021
ACTIVE
Biospecimen Resource for Hepatocellular Carcinoma Research
Role: Principal Investigator
Funding: MAYO CLINIC
Oct 2020
– Dec 2022
NFL/ Cancer Screening during COVID-19 Project 2020 – 2021
Role: Principal Investigator
Funding: AMERICAN CANCER SOCIETY
Sep 2020
– Nov 2022
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of
the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-
Severe Crohn's Disease
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via BRISTOL MYERS SQUIBB CO
Apr 2020
– Dec 2023
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of
the Safety and Efficacy of BMS-986165 in Subjects with Moderate to
Severe Ulcerative Colitis
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via BRISTOL MYERS SQUIBB CO
Mar 2020
– Aug 2024
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)
Role: Principal Investigator
Funding: EAST COAST INSTITUTE FOR RESEARCH
via ELI LILLY AND CO
Mar 2020
– Dec 2022
A Phase 2b, Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group Study to Assess the
Efficacy and Safety of Oral Etrasimod as Induction
Therapy in Subjects with Moderately to Severely Active
Crohns Disease
Role: Principal Investigator
Funding: IQVIA LTD
via ARENA PHARMACEUTICALS
Feb 2020
– Dec 2023
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Role: Principal Investigator
Funding: DRUGDEV INC
via ARENA PHARMACEUTICALS
Jan 2020
– Dec 2023
An Open-Label Extension Study of Etrasimod in
Subjects with Moderately to Severely Active
Ulcerative Colitis
Role: Principal Investigator
Funding: DRUGDEV INC
via ARENA PHARMACEUTICALS
Nov 2019
– Feb 2022
A Phase 3, Randomized, Double-Blind, Placebo-Controlled,
52-Week Study to Assess the Efficacy and Safety of Etrasimod in
Subjects with Moderately to Severely Active Ulcerative Colitis
Role: Principal Investigator
Funding: IQVIA LTD
via ARENA PHARMACEUTICALS
Jul 2018
– Jun 2024
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
Role: Principal Investigator
Funding: INTERCEPT PHARMACEUTICALS
Aug 2017
ACTIVE
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for
Inflammatory Bowel Disease
Role: Principal Investigator
Funding: TARGET PHARMASOLUTIONS dba TARGET RWE
May 2017
– Oct 2021
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Evaluating the Safety and Efficacy of Selonsertib in Subjects with
Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
Role: Principal Investigator
Funding: GILEAD SCIENCES
Mar 2017
– Mar 2021
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
Role: Project Manager
Funding: ABBVIE
Dec 2016
– Jun 2024
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Role: Principal Investigator
Funding: TARGET PHARMASOLUTIONS dba TARGET RWE
Dec 2016
ACTIVE
A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
Role: Principal Investigator
Funding: TARGET PHARMASOLUTIONS dba TARGET RWE
Nov 2016
ACTIVE
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled,
Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in
Subjects with Nonalcoholic Steatohepatitis
Role: Principal Investigator
Funding: INTERCEPT PHARMACEUTICALS
Jan 2016
– Mar 2022
Prioritize Study
Role: Project Manager
Funding: PATIENT-CENTERED OUTCOMES RES INST
Oct 2011
ACTIVE
HCV-TARGET Primary Operating Project with subprojects
Role: Project Manager
Funding: UF DIV OF SPONSORED RESEARCH
Education
Transplant Hepatology Fellowship
2005
·
Mayo Clinic
Gastroenterology Fellowship
2004
·
McGill University Health Center – Royal Victoria Hospital
Internal Medicine Residency
2001
·
McGill University Health Center – Royal Victoria Hospital
Doctor of Medicine
1998
·
McGill University
Contact Details
Phones:
- Business:
- (904) 244-8846
Emails:
- Business:
- maged.ghali@jax.ufl.edu
Addresses:
- Business Mailing:
-
653 W 8TH ST
JACKSONVILLE FL 32209 - Business Street:
-
653-1 W 8TH ST
108 BENT PINE CT
JACKSONVILLE FL 322096511